Follow our progress.

Milestones in our journey to reinvent genetic testing.

Press Releases

Invitae Study of 143,000 Patients Shows Importance of Routinely Including Deletion and Duplication Detection with Sequencing in Genetic Testing

Invitae Study of 143,000 Patients Shows Importance of Routinely Including Deletion and Duplication Detection with Sequencing in Genetic Testing

Junho 13, 2018

Approximately 10 Percent of Patients With Genetic Changes Associated with Disease Show Copy Number Variant Changes That May Go Undetected by Traditional Approaches

Researchers from Invitae, one of the fastest growing genetics companies, today published findings from the largest analysis to date of genetic testing to identify deletions and duplications involving single genes using next-generation sequencing (NGS) techniques. The study found that these changes, also called exonic copy number variants (CNVs), are present in a substantial number of patients and ...

Read more


Invitae to Present at the William Blair 2018 Growth Stock Conference

Invitae to Present at the William Blair 2018 Growth Stock Conference

Maio 30, 2018

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the William Blair 2018 Growth Stock Conference on Tuesday, June 12, 2018 at 4:10 p.m. Central / 5:10 p.m. Eastern / 2:10 p.m. Pacific in Chicago.

A live webcast of the presentation may be accessed by visiting the investors section of the company’s website at ir.invitae.com. A replay ...

Read more


Invitae Reports 169% Revenue Growth Driven by 150% Growth in Volume in First Quarter 2018

Invitae Reports 169% Revenue Growth Driven by 150% Growth in Volume in First Quarter 2018

Maio 09, 2018

Raising annual volume and revenue guidance
Q1 2018 gross profit of $9.6M up from $1.0M in Q1 2017
Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced financial and operating results for the first quarter ended March 31, 2018. Based on the growing momentum in test volume and substantial revenue growth, the company is increasing its volume guidance from accessioning ...

Read more


Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy

Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy

Maio 07, 2018

The program helps clinicians identify patients who may be eligible for Sarepta’s clinical trials

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced the expansion of its partnership with Sarepta Therapeutics, Inc. (NASDAQ: SRPT) to assist clinicians in identifying patients with Duchenne muscular dystrophy (DMD).

“Our partnership with is important to advancing our clinical study objectives across our entire RNA-based platform,” said Doug Ingram, Sarepta’s President and CEO. “Sarepta’s goal is to treat 100% of ...

Read more


Invitae Announces New Program to Offer Genetic Testing to Aid Diagnosis of Spinal Muscular Atrophy (SMA)

Invitae Announces New Program to Offer Genetic Testing to Aid Diagnosis of Spinal Muscular Atrophy (SMA)

Abril 27, 2018

Part of the Invitae Network, SMA Identified increases access to genetic testing for people with SMA

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it is launching a new program with Biogen, a leading biotechnology company, to offer genetic testing at no charge to patients suspected of having or clinically diagnosed with spinal muscular atrophy (SMA), a rare, progressive, genetic, neuromuscular disease. The program, SMA Identified, is the latest addition to Invitae’s network of ...

Read more


Invitae to Announce First Quarter 2018 Financial Results on May 9, 2018

Invitae to Announce First Quarter 2018 Financial Results on May 9, 2018

Abril 25, 2018

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it will report its first quarter 2018 financial results on Wednesday, May 9, 2018 and will host a conference call and webinar that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.

The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number ...

Read more


Invitae research highlights utility of proactive genetic screening, importance of assessing secondary findings in genetic testing

Invitae research highlights utility of proactive genetic screening, importance of assessing secondary findings in genetic testing

Abril 10, 2018

Data presented at annual American College of Medical Genetics meeting

Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, will present findings showing proactive genetic health screening reveals medically significant findings for a substantial portion of patients, and looking for secondary findings during genetic testing provides a substantial yield of actionable risk factors for disease. The studies are among the company’s data being presented this week at the American College of Medical Genetics (ACMG) annual ...

Read more


Invitae Announces Pricing of Public Offering of Common Stock

Invitae Announces Pricing of Public Offering of Common Stock

Março 28, 2018

Invitae Corporation (NYSE: NVTA) today announced the pricing on March 27, 2018 of an underwritten public offering of 11,111,111 shares of its common stock at a price to the public of $4.50 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $50.0 million. The offering is expected to close on ...

Read more


Invitae Announces Proposed Public Offering of Common Stock

Invitae Announces Proposed Public Offering of Common Stock

Março 26, 2018

Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae. In addition, Invitae expects to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The ...

Read more


Invitae expands network of patients in rare and ultra-rare diseases

Invitae expands network of patients in rare and ultra-rare diseases

Março 23, 2018

No Stomach For Cancer among five advocacy groups establishing registry networks to connect patients, clinicians and researchers

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced an expansion of its network of rare and ultra-rare patient registries in its Patient Insights NetworkTM (PIN) program to include five additional collaborations with leading advocacy groups across a variety of genetic conditions. The programs are designed to empower patients to be active participants in their networks and ...

Read more